Low-Dose Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Case Report

The effect of low -dose apalutamide in nonmetastatic castration -resistant prostate cancer is unknown. We report the observation of therapy being administered at 25% of the recommended dose in an 80 -year -old patient. Despite treatment discontinuation during COVID lockdowns, he survived three years without evidence of metastasis. This case gently invites us to reflect on the possibility of low -dose apalutamide in the elderly.